Entrada Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Entrada Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2024.
  • Entrada Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$14M, a 140% decline year-over-year.
  • Entrada Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was $55M.
  • Entrada Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$6.69M, a 92.9% increase from 2022.
  • Entrada Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$94.6M, a 84.9% decline from 2021.
  • Entrada Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$51.2M, a 92.9% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $55M -$14M -$49.5M -140% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $104M $55M +$81M Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-05
Q1 2024 $23.5M $23.5M +$30.2M Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-05
Q4 2023 -$6.69M -$9.54M +$15.1M +61.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-13
Q3 2023 -$21.8M $35.5M +$60.6M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 -$82.4M -$25.9M -$2.75M -11.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-05
Q1 2023 -$79.6M -$6.67M +$15M +69.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-05
Q4 2022 -$94.6M -$24.6M -$6.18M -33.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-13
Q3 2022 -$88.4M -$25.1M -$10.7M -74.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$77.7M -$23.2M -$13.3M -134% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-07
Q1 2022 -$64.4M -$21.7M -$13.3M -159% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-07
Q4 2021 -$51.2M -$18.4M -$9.77M -113% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-06
Q3 2021 -$41.4M -$14.4M -$7.44M -106% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$33.9M -$9.9M -$3.73M -60.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-07
Q1 2021 -$30.2M -$8.38M -$3.69M -78.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-07
Q4 2020 -$26.5M -$8.67M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-15
Q3 2020 -$6.99M Jul 1, 2020 Sep 30, 2020 10-Q 2021-12-09
Q2 2020 -$6.17M Apr 1, 2020 Jun 30, 2020 10-Q 2021-12-09
Q1 2020 -$4.69M Jan 1, 2020 Mar 31, 2020 10-Q 2021-12-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.